Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05166096 · ClinicalTrials.gov registry record · Phase 1

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

A Phase 1 study of Healthy, sponsored by Rhoshan Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05166096: Completed Phase 1 study of Healthy, sponsored by Rhoshan Pharmaceuticals.

NCT05166096 is a Phase 1 study of Healthy that has completed, run by Rhoshan Pharmaceuticals. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05166096, a Phase 1 study of Healthy, has completed, sponsored by Rhoshan Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.

Conditions Studied

Interventions

  • DRUG Rho-11
  • DRUG aspirin 325mg

Study Locations (1)

Texas

  • PPD Early Development - Austin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-12-03
Est. Completion 2022-05-11
Phase Phase 1

Sponsor

Rhoshan Pharmaceuticals

1 total trials

What the Registry Record Tells You About NCT05166096

The ClinicalTrials.gov registry entry for NCT05166096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Rhoshan Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Rho-11 is the first listed.

NCT05166096 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05166096 about?

NCT05166096 is a clinical study titled "Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects". The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.

What is the current status of trial NCT05166096?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-12-03. Estimated completion is 2022-05-11.

What conditions does trial NCT05166096 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05166096?

The interventions under investigation include: Rho-11 (DRUG), aspirin 325mg (DRUG).

Who is sponsoring clinical trial NCT05166096?

This trial is sponsored by Rhoshan Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05166096 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.